RxDoctor Payments DataLook up a doctor →

Kristen Bamber

Interventional Pain Medicine · Dublin, OHNPI 1376931535

Payments from drug & device makers

$11,319in general payments, 2019–2025

Across 581 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boston Scientific$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$917
  • Collegium Pharmaceutical, Inc.$746
  • Pfizer$572
  • Biohaven Pharmaceutical Holding Company Ltd.$552
  • plus $4K from 22 others

What the payments were for

  • Food & beverage$11,311100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,319 in reported general payments places this provider in the 65th percentile of 67 interventional pain medicine providers in Ohio.

See all interventional pain medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$28,269
Medicare patients
113
Services billed
697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen213$16,765
Xtampza ErOxycodone Myristate20$13,645
Methocarbamol49$10,113
Buprenorphine32$8,205
Fentanyl51$7,835
BelbucaBuprenorphine Hcl14$7,694
Gabapentin197$2,933
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen128$2,429
Morphine Sulfate ErMorphine Sulfate76$1,675
Pregabalin52$1,143
Tizanidine Hcl150$1,017
Methadone Hcl28$557
Cyclobenzaprine Hcl68$541
Oxycodone Hcl35$465
Acetaminophen-CodeineAcetaminophen With Codeine20$325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$746$21,33934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 67 interventional pain medicine providers in Ohio.

Other interventional pain medicine in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →